AccuCheck

K250696 · Manteia Technologies Co., Ltd. · IYE · Oct 24, 2025 · Radiology

Device Facts

• Record ID: K250696
• Device Name: AccuCheck
• Applicant: Manteia Technologies Co., Ltd.
• Product Code: IYE · Radiology
• Decision Date: Oct 24, 2025
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 892.5050
• Device Class: Class 2
• Attributes: Software as a Medical Device

Intended Use

AccuCheck is a quality assurance software to the quality assurance of general offline planning, online adaptive planning and various radiotherapy technology such as photon and proton. It is used for data transfer integrity check, secondary dose calculation with Monte Carlo algorithm, and treatment plan verification in radiotherapy. AccuCheck also provides independent dose verification based on Accelerator delivery log after radiotherapy plan execution. AccuCheck is not a treatment planning system or a radiation delivery device. It is to be used only by trained radiation oncology personnel for quality assurance purposes.

Device Story

AccuCheck is a standalone radiotherapy quality assurance (QA) software system. It ingests DICOM RT data (CT, CBCT, MR, RTStruct, RTPlan, RTDose) and accelerator delivery logs. The device performs data transfer integrity checks, secondary dose calculations using a Monte Carlo algorithm, and treatment plan verification. It includes modules for TPS parameter checking, independent pre-treatment dose calculation, transfer verification, and post-treatment log-based dose verification. The system provides auxiliary analysis tools including DVH graphs, gamma analysis, target coverage, and clinical goal evaluation. Used in clinical settings by radiation oncology personnel, the output assists clinicians in verifying plan accuracy and machine delivery stability. It does not deliver radiation or serve as a treatment planning system; it acts as an independent verification layer to ensure treatment plan integrity and patient safety.

Clinical Evidence

No clinical studies were performed. Evidence consists of bench-level software verification and validation testing, and compatibility testing with Varian, Elekta, and Accuray equipment. Secondary dose calculation accuracy was validated using 20 patient cases (Brain, Lung, Head and Neck, GI) treated with IMRT, VMAT, TOMO, and Proton techniques. Metrics included DVH, dose indices, 3D dose distribution, dose profiles, and 3D gamma passing rates compared against FDA-cleared TPS.

Technological Characteristics

Standalone software running on Windows OS. Uses Monte Carlo algorithm for independent dose calculation. Supports DICOM RT standards (CT, CBCT, MR, RTStruct, RTPlan, RTDose). Connectivity via data transfer from TPS and accelerator logs. No patient contact; no electrical/mechanical components.

Indications for Use

Indicated for quality assurance of radiotherapy planning and delivery, including photon and proton modalities, for patients undergoing radiotherapy. Intended for use by trained radiation oncology personnel.

Regulatory Classification

Identification

A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.

Predicate Devices

• AccuCheck 1.1 (K223834)

Submission Summary (Full Text)

{0}

FDA U.S. FOOD & DRUG ADMINISTRATION

October 24, 2025

Manteia Technologies Co., Ltd.
Chao Fang
Quality Manager
Unit 3001-3005, No.5 Huizhan North Road
Xiamen, Fujian 361008
China

Re: K250696
Trade/Device Name: AccuCheck
Regulation Number: 21 CFR 892.5050
Regulation Name: Medical Charged-Particle Radiation Therapy System
Regulatory Class: Class II
Product Code: IYE
Dated: March 7, 2025
Received: March 7, 2025

Dear Chao Fang:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov

{1}

K250696 - Chao Fang
Page 2

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-

{2}

K250696 - Chao Fang
Page 3

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,


Lora D. Weidner, Ph.D.
Assistant Director
Radiation Therapy Team
DHT8C: Division of Radiological
Imaging and Radiation Therapy Devices
OHT8: Office of Radiological Health
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

{3}

AccuCheck
Page 8 of 39

| Indications for Use | | |
| --- | --- | --- |
| Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K250696 | ? |
| Please provide the device trade name(s). | | ? |
| AccuCheck | | |
| Please provide your Indications for Use below. | | ? |
| AccuCheck is a quality assurance software to the quality assurance of general offline planning, online adaptive planning and various radiotherapy technology such as photon and proton. It is used for data transfer integrity check, secondary dose calculation with Monte Carlo algorithm, and treatment plan verification in radiotherapy. AccuCheck also provides independent dose verification based on Accelerator delivery log after radiotherapy plan execution.
AccuCheck is not a treatment planning system or a radiation delivery device. It is to be used only by trained radiation oncology personnel for quality assurance purposes. | | |
| Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C) | |

{4}

K250696
1 of 5
510(k) Summary

# 510(k) Summary

The following information is provided as required by 21 CFR 807.92.

The assign 510(k) Number: K250696

# I. SUBMITTER

Manteia Technologies Co., Ltd.
Unit 3001-3005, No.5 Huizhan North Road, Xiamen City, Xiamen, Fujian, P.R. China
Establishment Registration Number: 3016686005
Contact Person: Chao Fang
Position: Quality Manager
Email: [e-mail]
Date of Prepared: 03/07/2025

# II. DEVICE

Subject Device/Trade Name: AccuCheck
Common Name: AccuCheck Radiotherapy Plan Quality Assurance System
Classification Name: accelerator, linear, medical
Classification: II
Product Code: IYE
Regulation Number: 21 CFR 892.5050
Review Panel: Radiology

# III. PREDICATE DEVICE

Predicate Device: AccuCheck 1.1 (K223834)

# IV. DEVICE DESCRIPTION

AccuCheck, defined as a radiotherapy plan quality assurance system, aims to improve the clinical efficiency of offline and online quality control. AccuCheck supports Monte Carlo dose calculation engine, and is applicable to the quality assurance of general offline planning, online adaptive planning and various radiotherapy technology such as photon and proton.

AccuCheck is to be used for the quality assurance of offline plans and online adaptive radiotherapy plans, where the TPS Check module is used to check whether the parameters related to treatment plan are within the executable range of the machine; the Dose Check module is designed to use an independent dose calculation engine to re-calculate the original plan before the treatment, and is compared with the dose of the original plan; the Transfer Check module could verify whether errors are occurred during transferring from the TPS system to the accelerator; the Log Check module is used to obtain execution log of each

1 / 5

{5}

510(k) Summary

execution of the accelerator, calculate dose through an independent dose calculation engine, and compare it with the dose of original plan; Treatment Summary supports physical dose accumulation of doses executed multiple times for a single plan, which reflect the stability of the accelerator operating, it could at the same time support the reconstruction of log to the fractional images so as to evaluate the daily exposure dose of the patient. AccuCheck provides abundant auxiliary analysis tools, including DVH Graph, Gamma Analysis, Target Coverage, Gamma Pass Rate of each ROI, Dose Statistics, and Clinical Goals Evaluation.

# V. INDICATIONS FOR USE

AccuCheck is a quality assurance software to the quality assurance of general offline planning, online adaptive planning and various radiotherapy technology such as photon and proton. It is used for data transfer integrity check, secondary dose calculation with Monte Carlo algorithm, and treatment plan verification in radiotherapy. AccuCheck also provides independent dose verification based on Accelerator delivery log after radiotherapy plan execution.

AccuCheck is not a treatment planning system or a radiation delivery device. It is to be used only by trained radiation oncology personnel for quality assurance purposes.

# VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

The main changes in the subject device compared with the predicate device are as follow:

- Dose Check Feature

□New-add Treatment Techniques - TomoTherapy and Pencil Beam Scanning (PBS)
□New-add Beam type - Proton

- Log Check Feature

□New-add Treatment Techniques - Pencil Beam Scanning (PBS)
□New-add Beam type - Proton

The detailed comparison of technical parameters is shown in the table below.

| ITEM | Subjective Device AccuCheck | Predicate Device AccuCheck (K223834) |
| --- | --- | --- |
| Regulatory Information | | |
| Regulation No. | 21CFR 892.5050 | 21CFR 892.5050 |
| Product Code | IYE | IYE |
| Class | II | II |
| Indications of Use | AccuCheck is a quality assurance software to the quality assurance of general offline planning, online adaptive planning and various radiotherapy technology such as photon and proton. It is used for data transfer integrity check, secondary dose calculation with Monte Carlo algorithm, and treatment plan verification in radiotherapy. AccuCheck also provides independent dose verification based | |
| | | on the data transfer integrity check, secondary dose calculation with Monte Carlo algorithm, and treatment plan verification in radiotherapy. AccuCheck also provides independent dose verification based on Accelerator delivery log after radiotherapy plan execution. |

{6}

510(k) Summary

| | algorithm, and treatment plan verification in radiotherapy. AccuCheck also provides independent dose verification based on Accelerator delivery log after radiotherapy plan execution. AccuCheck is not a treatment planning system or a radiation delivery device. It is to be used only by trained radiation oncology personnel for quality assurance purposes. | on LINAC delivery log after radiotherapy plan execution. AccuCheck is not a treatment planning system or a radiation delivery device. It is to be used only by trained radiation oncology personnel for quality assurance purposes. |
| --- | --- | --- |
| Intended User | Trained radiation oncology personnel. | Trained radiation oncology personnel. |
| Operating System | Windows | Windows |
| Independent Software | YES | YES |
| Technological Characteristics | | |
| TPS Check | YES | YES |
| Dose Check | YES | YES |
| Transfer Check | YES | YES |
| Log Check | YES | YES |
| Patient Management Feature | | |
| Auto Check | YES | YES |
| Manual Check | YES | YES |
| Patient List Display | YES | YES |
| Plan List Display | YES | YES |
| Plan Check Results Display | YES | YES |
| DICOM RT | YES (Supports CT, CBCT, MR, RTStruct, RTPlan, RTDose) | YES (Supports CT, CBCT, MR, RTStruct, RTPlan, RTDose) |
| TPS Check Feature | | |
| Supported Treatment Techniques | 3D-CRT, IMRT, VMAT, SRS, SBRT | 3D-CRT, IMRT, VMAT, SRS, SBRT |
| Check Results Display | YES | YES |
| Check Results Export | YES | YES |
| Dose Check Feature | | |
| Supported Treatment Techniques | 3D-CRT, IMRT, VMAT, SRS, SBRT, TomoTherapy, PBS | 3D-CRT, IMRT, VMAT, SRS, SBRT |
| Supported DICOM Data | CT, CBCT, MR, RTStruct, RTPlan, RTDose | CT, CBCT, MR, RTStruct, RTPlan, RTDose |
| Beam Type | Photon, Proton | Photon |
| Dose Calculation Algorithm | Monte Carlo algorithm | Monte Carlo algorithm |

{7}

510(k) Summary

| Dose Comparison | YES | YES |
| --- | --- | --- |
| Check Results Display | YES | YES |
| Check Results Export | YES | YES |
| Transfer Check Feature | | |
| Supported Treatment Techniques | 3D-CRT, IMRT, VMAT, SRS, SBRT | 3D-CRT, IMRT, VMAT, SRS, SBRT |
| Consistency Check based on transferred plan | YES | YES |
| Check Results Display | YES | YES |
| Check Results Export | YES | YES |
| Log Check Feature | | |
| Accelerator Log Analysis | Varian accelerators’ log files, Elekta accelerators’ log files | Varian accelerators’ log files, Elekta accelerators’ log files |
| Supported Treatment Techniques | 3D-CRT, IMRT, VMAT, SRS, SBRT, PBS | 3D-CRT, IMRT, VMAT, SRS, SBRT |
| Beam Type | Photon, Proton | Photon |
| Dose Calculation Algorithm | Monte Carlo algorithm | Monte Carlo algorithm |
| Dose Comparison | YES | YES |
| Check Results Display | YES | YES |
| Check Results Export | YES | YES |

## VII. PERFORMANCE DATA

The following performance data were provided in support of the substantial equivalence determination.

### Biocompatibility Testing

AccuCheck is a standalone software and will not come in contact with the patient, thus biocompatibility testing is not applicable.

### Electrical Safety and Electromagnetic Compatibility (EMC)

Not Applicable (Standalone Software).

### Software Verification and Validation Testing

Software verification and validation testings were conducted, and documentation was provided as recommended by FDA's Guideline for Industry and FDA Staff - Content of Premarket Submission for Device Software Functions. Verification and validation of the software was conducted to ensure that the product meet users needs and intended use. AccuCheck passed all software verification and validation tests.

{8}

510(k) Summary

## Compatibility Test of AccuCehck with TPS and Accelerator

The compatibility test was performed for 2 samples including treatment plans and treatment logs. The test samples used a compatible combination of Accelerator and TPS. The result of all test cases were passed and the following items were checked during the test: dose-volume histogram (DVH), dose index, 3D dose distribution, dose profile, gamma distribution, pass/fail results for the dose-volume histogram (DVH) limits, the 3D gamma passing rate, and differences in dose indices between the subject device and the FDA cleared TPS.

The test validates the compatibility of AccuCheck with TPS and Accelerator, for which are typical equipment from Varian, Elekta and Accuray.

## Verification and Validation Test on Secondary Dose Calculation

The test was performed for 20 patients respectively with Brain, Lung, Head and Neck, and GI cancers that have been treated with IMRT, VMAT, TOMO and Proton techniques. The result of all test cases were passed and the following items were checked during the test:

The dose-volume histogram (DVH), dose index, 3D dose distribution, dose profile, gamma distribution, pass/fail results for the dose - volume histogram (DVH) limits, the 3D gamma passing rate, and differences in dose indices between the subject device and the FDA cleared TPS.

## Mechanical and Acoustic Testing

Not Applicable (Standalone Software).

## Animal Study

Not Applicable (Standalone Software).

## Clinical Studies

Clinical trials were not performed as part of the development of this product. Clinical testing on patients is not advantageous in demonstrating substantial equivalence or safety and effectiveness of the device since testing can be performed such that no human subjects are exposed to risk.

## VIII. CONCLUSIONS

AccuCheck is believed to be substantially equivalent to the predicate device in terms of its indications for use, technical characteristics, and overall performance. The information provided in this submission indicates substantial equivalence to the predicate device.

Therefore, Manteia Technologies Co., Ltd. considers the subjective device, AccuCheck, is substantially equivalent to the predicate device AccuCheck (K223834).